Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y400 intravitreal dose-escalation study in neovascular age-related macular degeneration
ChiCTR2300072757Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Eye Hospital
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Y400 in exudative macular degeneration (5 arms), sponsored by Tianjin Medical University Eye Hospital. Primary endpoints: Incidence and severity of ocular local adverse events including dose-limiting toxicities and Maximum tolerated dose and recommended phase 2 dose. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
Y400
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on ChiCTR2300072757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072757.